Roche’s Avastin as Good as Novartis AG’s Lucentis for AMD

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Published in the Lancet on Friday, a trial has been claiming that the NHS should make use of an unlicensed drug, cheaper than the licensed one, to treat people at risk of going blind. Since, the same could help it save almost £84m or more each year. It was being questioned if Avastin, the cancer drug, was safe to cure people suffering from wet age-related macular degeneration (AMD).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC